Study of the relative bioavailability of a multisource formulation of sulfamethoxazole regarding the drug reference
DOI:
https://doi.org/10.24265/horizmed.2016.v16n3.03Keywords:
Relative bioavailability, Bioequivalence, Sulfamethoxazole, Multisource drug, Drug referenceAbstract
Objective: To determine the relative bioavailability of an oral formulation of multisource sulfamethoxazole 200 mg / 5 ml respect to the reference formulation Oryctolagus cuniculus L (albino rabbits). Material and methods: The samples studied consisted of 25 vials of suspension of sulfamethoxazole / trimethoprim multisource 200 mg: 40 mg / 5 ml T1 with the letter assigned to the batch 11070674; and as a reference (R) 25 flasks Bactrim suspension of 200 mg: 40 mg / 5 ml, RJ0774 batch. The protocol consisted of a single oral dose of 100 mg / kg of sulfamethoxazole 200 mg / 5 ml of each of the formulations to 12 albino rabbits after a 12 hour fasting, through an open design in two cross periods (T / R), randomized, double-blind study with a greater range of 5 half-lives between each administration, later to determine plasma concentrations of the drug in default until 12 hours by means of a spectrophotometric method periods of time colorimetric diazotization. With the data of plasma, bioavailability curves were constructed, including the area under the curve (ABCo-12h , ABCo-∞ ), Cmax and tmax were determined. Results: According to statistical analysis for bioequivalence, it was found: ABCo-12h T1 / ABCo-12h R CI 90% from 0.873 to 1.021, AUCo-∞ T1 / AUCo-∞ R 90% CI 0.868 to 1.032 and Cmax T1 / Cmax R CI 90% 0,866- 1,045. Conclusions: The values of multisource sulfamethoxazole found are within the acceptable range of bioequivalence proposed by WHO and the FDA(0.80-1.25), demonstrating the bioequivalence of multisource T1 respect to the reference.
Downloads
References
World Health Organization. Multisource (generic) Pharmaceutical Products: Guidelines on registration requirements to establish interchangeability. Revision. Working document QAS/14.583. Geneva, 2014.
Saavedra I, Ortiz M, Quiñones L, Ortiz M, Sasso J, Varela N, et al. Estudio de biodisponibilidad relativa de una formulación similar de aripiprazol respecto al producto innovador del mercado farmacéutico. Laboratorio de Farmacocinética y Biodisponibilidad. Centro de Investigaciones Farmacológicas y Toxicológicas, Programa de Farmacología, Facultad de Medicina de la Universidad de Chile. 2011.
World Health Organization. International Nonproprietary Names for Pharmaceutical Substances (INN). WHO Drug Information, 2011;25( 4)2:413-465.
Saavedra I, Saldaña A, Ruminot C. Medicamentos Genéricos. Cuadernos Médico Sociales 2006; 46(3):205-211.
Laosa O, Guerra P, López-Durán J, Mosquera B, Frías J. Estudios de bioequivalencia: la necesidad de establecer la fiabilidad de los medicamentos genéricos. Rev Perú Med Exp Salud Pública 2009; 26(4): 553-562.
Alfonso R, Andia T, Barbosa T, Watanabe J. Definition and Classification of Generic Drugs Across the World. Appl Health Econ Health Policy 2015; 13 (1):5-11.
Saavedra I, Quiñones L, Sasso J, Saavedra M, Gaete L, et al. Estudio de biodisponibilidad relativa entre dos formulaciones orales de micofenolato mofetilo en voluntarios sanos. Rev Med Chile 2011;139:902-908.
Chow S. Bioavailability and Bioequivalence in Drug Development. Wiley Interdiscip Rev Comput Stat. 2014 ; 6(4): 304–312.
Alonso R, Bernardo R, Valle D, Gonzlilez M, Namur S, Burke V, et al. Bioequivalence of Two Commercial Preparations of Trimethoprim/Sulfamethoxazole: A Randomized, Single-Dose, Single-Blind, Crossover Trial. Clinical Therapeutics 2007;29(2): 326-333.
Velasco A, San Román L, Serrano J, Martínez R, Cadavid M. Farmacología Fundamental. Madrid: McGraw-Hill Interamericana; 2002.
Mendoza N. Farmacología médica. México: Editorial Médica Panamericana; 2008.
Bruton L, Lazo J, Parker K. Goodman-Gilman Las bases farmacológicas de la Terapéutica. 11 ed. Colombia: McGrawHill Interamericana; 2007.
Rang H, Dale M, Ritter J. Farmacología. 4 ed. Madrid: Editorial Harcourt; 2000.
Lorenzo P, Moreno A, Leza J, Lizasoain I, Moro M. Velásquez Farmacología Básica y Clínica. Madrid: 17 ed. Editorial Médica Panamericana; 2005.
Katzung B. Farmacología básica y clínica. México: 9 ed. Manual Moderno; 2005.
Manzo R. Implicancias de la clasificación biofarmacéutica de los fármacos en las regulaciones sobre equivalencia farmacéutica y bioequivalencia y en la práctica farmacéutica. Córdova: Facultad de Ciencias Químicas. Universidad Nacional de Córdova; 2006.
Amini H, Ahmadiani A. Rapid and simultaneous determination of sulfamethoxazole and trimethoprim in human by highperformance liquid chromatog raphy. Journal of Pharmaceutical and Biomedical Analysis 2007; 43(3):1146- 1150.
Pierce D, Corcoran M, Martin P, Barrett K, Inglis S, Preston P, et al. Effect of MMX mesalamine coadministration on the pharmacokinetics of amoxicillin, ciprofloxacin XR, metronidazole, and sulfamethoxazole: results from four randomized clinical trials. Drug Design, Development and Therapy 2014;8: 529543.
Center for Drug Evaluation and Research (CDER). Food and Drug Administration. Guidance for Industry Bioavailability and Bioequivalence Studies for Orally Administered Drug Products — General Considerations Rockville, 2003.
Buitrago A, González S, Calderón L. Validación de un método espectrofotométrico para la determinación de clorhidrato de bromhexina en formas farmacéuticas líquidas, basada en la reacción de Bratton-Marshall. Revista de la Facultad de Farmacia 2005;47(1):10-16.
Guzmán F. Estudio analítico de sulfamidas, compuestos asociados y productos de degradación mediante nuevos métodos de separación [tesis]. Castilla (España): Universidad de Castilla-La Mancha; 2001. 344 p.
Domínguez-Gil A. Los medicamentos genéricos y el 20%. Revista Española de Economía en Salud 2009; 6:266-267.
Amin A, Shahat M, Edeen R, Meshref M. Comparison of Ionpairing and Reversed Phase Liquid Chromatography in Determination of sulfamethoxazole and trimethoprim. Analytical Letters 2008; 41(10): 1878-1894.
Chakwenya J, Lakritz J, Tyler J, Fales W, James-Kracke M, Smith K, et al. Pharmacokinetics and bioavailability of trimethoprim-sulfamethoxazole in alpacas. J. Vet Pharmacol Ther. 2002; 25(5): 321-7.
Hutt V, Klongmann I, Pabst G, Salama Z, Nieder M, Jaeger H. Studies of the pharmacokinetics and bioavailability of a new trimethoprim/ sulfamethoxazole preparation in healthy volunteers. 1988; 38(9):1347-50.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2016 Horizonte Médico (Lima)
This work is licensed under a Creative Commons Attribution 4.0 International License.
Horizonte Médico (Lima) (Horiz. Med.) journal’s research outputs are published free of charge and are freely available to download under the open access model, aimed at disseminating works and experiences developed in biomedical and public health areas, both nationally and internationally, and promoting research in the different fields of human medicine. All manuscripts accepted and published in the journal are distributed free of charge under the terms of a Creative Commons license – Attribution 4.0 International (CC BY 4.0).
